Amgen/UCB’s osteoporosis drug hit by cardio risk
Amgen and UCB have suffered a setback to their osteoporosis drug, romosozumab, after first phase 3 trial results revealed a heart safety signal. Evenity, as it will be branded if approved, is under review with the FDA, which had been due to make a decision on the drug in July.